4-(2-hydroxybenzyl)benzonitrile | 500294-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-hydroxybenzyl)benzonitrile
• 英文别名: 4-[(2-Hydroxyphenyl)methyl]benzonitrile
• CAS: 500294-79-1
• 化学式: C₁₄H₁₁NO
• 分子量: 209.247
• InChiKey: JTESIALXBONBEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-hydroxybenzyl)benzonitrile 在 palladium(II) hydroxide/carbon 三丁基膦 、 偶氮二甲酰胺 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 37.0h， 生成 [2-(4-aminomethylbenzyl)phenyl]-2,3,4,5-tetra-O-benzyl-5a-carba-β-D-glucopyranoside
  参考文献：
  名称：

  EP1783110

  摘要：

  公开号：
• 作为产物：
  描述：

  2-溴苯酚 在 三乙基硅烷 、 正丁基锂 、 三氟乙酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 4-(2-hydroxybenzyl)benzonitrile
  参考文献：
  名称：

  [EN] NOVEL THYROMIMETICS
  [FR] NOUVEAUX THYROMIMÉTIQUES

  摘要：

  提供具有以下结构的化合物（I）的结构：或其药学上可接受的异构体、拉氏体、水合物、溶剂合物、同位素或盐，其中A、X1、X2、Q、R1、R2和n如本文所定义。这些化合物作为甲状腺类似物发挥作用，并可用于治疗神经退行性疾病和纤维化疾病等疾病。还提供含有这些化合物的药物组合物，以及它们的使用和制备方法。

  公开号：

  WO2020180624A1

文献信息

• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• NaNO₂-catalyzed reaction of cyclohexenone-MBH acetates: A convenient synthesis of 2-methylene-3-cyclohexenones
  作者：Lin Jiang、Lu Li、Min Li、Ming-Wei Yuan、Ming-Long Yuan

  DOI：10.1080/00397911.2023.2235625

  日期：2023.9.17

  Abstract An efficient NaNO2-catalyzed synthesis of 2-methylene-3-cyclohexenones from easily accessible cyclohexenone-MBH acetates has been established for the first time. Target products were rapidly generated in moderate to high yields and with relatively high E/Z selectivity. Easy operation, good functional group tolerance, mild reaction conditions and the practicality of high efficiency of NaNO2

  摘要 首次建立了NaNO 2催化从容易获得的环己烯酮-MBH乙酸酯合成2-亚甲基-3-环己烯酮的方法。目标产物快速生成，产率中等至较高，且E/Z选择性较高。操作简便、官能团耐受性好、反应条件温和以及NaNO 2高效生成2-亚甲基-3-环己烯酮的实用性构成了该反应的诱人优点。
• NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1783110A1

  公开（公告）日：2007-05-09

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优越性能，如持久的药物活性、代谢稳定性和安全性；以及一种药物组合物，用于预防或治疗由高血糖引起的疾病，如糖尿病，如胰岛素依赖型糖尿病（1型糖尿病）或非胰岛素依赖型糖尿病（2型糖尿病）、糖尿病并发症和肥胖症。衍生物是由式（I）代表的化合物： (其中 A 是-O-、-CH2-或-NH-；n 是选自 0 和 1 之间的整数；R6 和 R7 各自独立地是氢或 C1-6 烷基；m 是选自 1-3 之间的整数；Q 是选自下式 Q1 至 Q5 之间的整数； Ar1是任选取代的芳基或任选取代的杂芳基，条件是杂芳基可以键合到芳香族碳环或芳香族杂环上以形成融合环；以及Ar2是任选取代的芳基或任选取代的杂芳基）、该化合物的原药或二者的药学上可接受的盐。还提供了含有该化合物的药物、药物组合物或类似物。
• 10.3762/bjoc.20.130
  作者：Li, Lu、Li, Na、Mo, Xiao-Tian、Yuan, Ming-Wei、Jiang, Lin、Yuan, Ming-Long

  DOI：10.3762/bjoc.20.130

  日期：——

  Abstract A catalyst- and additive-free synthesis of 2-benzyl N-substituted anilines from (E)-2-arylidene-3-cyclohexenones and primary amines has been reported. The reaction proceeds smoothly through a sequential imine condensation–isoaromatization pathway, affording a series of synthetically useful aniline derivatives in acceptable to high yields. Mild reaction conditions, no requirement of metal catalysts

   抽象的 已经报道了由( E )-2-亚芳基-3-环己烯酮和伯胺无催化剂和无添加剂合成2-苄基N-取代苯胺。该反应通过连续的亚胺缩合-异构芳构化途径顺利进行，以可接受的高收率提供了一系列合成上有用的苯胺衍生物。温和的反应条件、不需要金属催化剂、操作简单和扩大生产的潜力是这种转变的一些突出优点。 贝尔斯坦 J. 组织。化学。 2024, 20, 1468–1475。 doi:10.3762/bjoc.20.130
• NOVEL THYROMIMETICS
  申请人：Autobahn Therapeutics, Inc.

  公开号：US20210053917A1

  公开（公告）日：2021-02-25

  Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X 1 , X 2 , Q, R 1 , R 2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.